Type 2 Diabetes Mellitus is the Risk Factor for Multi-drug Resistance Tuberculosis: A Meta-Analysis
DOI:
https://doi.org/10.26911/jepublichealth.2025.10.03.12Abstract
Background: Type 2 Diabetes Mellitus (T2DM) has a significant risk of developing active Tuber-culosis (TB) and complicates its treatment. There is no conclusive evidence on whether TB-T2DM comorbidities are associated with an increased risk of Multidrug Resistant Tuberculosis (MDR-TB). The study aims to analyze and estimate the relationship of T2DM to MDR-TB incidence and to estimate the size of the combined effect.
Subjects and Method: This study was a meta-analysis with PICO, Population: patients actively undergoing MDR-TB treatment. Intervention: Patients with comorbid Type 2 Diabetes Mellitus. Comparison: Tuberculosis patients without comorbid Type 2 diabetes mellitus. Output: MDR-TB (Multidrug Resistant Tuberculosis). The articles used in this study were obtained from databases with keywords to search for articles were ("Diabetes Mellitus, Type 2" OR "diabetic" OR "diabetes") AND "tuberculosis" AND ("Tuberculosis, Multidrug-Resistant" OR "drug resistance" OR "multidrug-resistant" OR "multidrug resistant" OR "multidrug resistance" OR "drug-resistant" OR "drug resistant"). Articles were selected based on inclusion criteria, is published in the form of an English full-text article from January 2015 to January 2025, reporting the relationship between T2DM and MDR-TB among TB patients. The articles were selected using the PRISMA flow diagram and analyzed using the Review Manager 5.3 application.
Results: This meta-analysis consisted of 9 articles originating from Europe, Asia, Africa and America. Results of the meta-analysis showed that the cohort study of type 2 diabetes mellitus had a 4.11 times greater risk of developing MDR-TB compared to people who did not have type 2 diabetes mellitus. In a control case study of type 2 diabetes mellitus, there was a 3.11 times greater risk of developing MDR-TB than people without type 2 diabetes mellitus, and both were statistically significant (aOR= 3.39; CI 95%= 2.05 to 8.24; p= 0.001).
Conclusion: Type 2 diabetes mellitus is a risk factor for MDR TB.
References
Adane HT, Howe CH, Wassie L, Magee MJ (2023). Diabetes mellitus is associated with an increased risk of unsuccessful treatment outcomes among drug susceptible tuberculosis patients in Ethiopia: A prospective health facility-based study. J Clin Tuberc Other Mycobact Dis. 31:100368. doi: 10.1016/j.jctube.2023.100368.
Saktiawati AMIS, Subranto YW (2018). Influence of Diabetes Mellitus on the Development of Multi Resistant Tuberculosis in Yogyakarta. Acta Med Indones. 50(1):591–593. doi: 10.1055/s-2008-1048255.
Cai X, Xu X, He G, Jiang X, Wu L (2024). Drug resistance in drug-resistant tuberculosis patients with and without diabetes mellitus: a comparative analysis. BMC Infect Dis. 24(1). doi: 10.1186/s12879-024-09712-3.
Cao R, Iskamoglu H, Teskey G, Gyurjian K, Abrahem R, Onajole OK, Lun S, et al. (2020). The preclinical candidate indole 2 carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes. Int Microbiol. 23(2):161–170. doi: 10.1007/S10123-019-00086-0.
Diana, Sanusi A, Nasir M (2020). Tuberkulosis Multidrug-Resistant Diabetes Mellitus Tipe 2. J Prof Medika. 2(3):235–242.
Gómez GA, Aquino MM, Meza SL, Alvarez MA, Ornelas DED, Segura MGH, Lezama MAS, et al. (2015). Diabetes and other risk factors for multidrug resistant tuberculosis in a Mexican population with pulmonary tuberculosis: case-control study. Arch Med Res. 46(2):142–148. doi: 10.1016/j.arcmed.2015.01.006.
Hu Y, Zheng X, Forsman LD, Ning Z, Chen C, Gao Y, Zhang Z, et al. (2021). Emergence of additional drug resistance during treatment of multidrug resistant tuberculosis in China: a prospective cohort study. Clin Microbiol Infect. 27(12):1805–1813. doi: 10.1016/j.cmi.2021.04.001.
Huangfu P, Gil CU, Golub J, Pearson F, Critchley J (2019). The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis. 23(7):783–796. doi: 10.5588/ijtld.18.0433.
IDF Diabetes Atlas (2021). IDF Diabetes Atlas. 10th ed. International Diabetes Federation.
Irawan B, Candra B, Yunus A (2020). Tuberculosis (TB) patient Diabetes Mellitus Type 2 (DMT2). Jember University.
Ministry of Health of the Republic of Indonesia (2023). Basic Health Research Report (Riskesdas). Jakarta: Ministry of Health of the Republic of Indonesia.
Lee EH, Lee JM, Kang YA, Leem YA, Kim YE, Jung JY, Park MS, et al. (2017). Prevalence and impact of diabetes mellitus among patients with active pulmonary tuberculosis in South Korea. Lung. 195(2):209–215. doi: 10.1007/s00408-017-9978-4.
Liu Q, Li W, Xue M, Chen Y, Du X, Wang C, Han L, et al. (2017). Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep. 7(1):1–7. doi: 10.1038/s41598-017-01213-5.
Navarro LMP, Restrepo BI, Dominguez FJF, Duggirala R, Romero JM, Alvarenga JCL, Comas I, et al. (2017). The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Tuberculosis (Edinb). 103:83–91. doi: 10.1016/j.tube.2017.01.006.
Lyu M, Wang D, Zhao J, Yang Z, Chong W, Zhao Z, Ming L, et al. (2020). A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitus. Int J Infect Dis. 97:69–77. doi: 10.1016/j.ijid.2020.05.080.
Muñoz-Torrico M, Caminero LJ, Migliori GB, D'Ambrosio L, Carrillo A, Jose L, Villareal VH, et al. (2017). Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis. Arch Bronconeumol. 53(5):245–250. doi: 10.1016/j.arbres.2016.10.021.
Murti B (2020). Principles and methods of epidemiological research. Surakarta: IKM Study Program, Postgraduate Program, Sebelas Maret University.
Nowinski A, Wesolowski S, Kosela MK (2023). The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study. Front Public Health. 11:1253615. doi: 10.3389/fpubh.2023.1253615.
Rehman A, Khattak M, Mushtaq U, Latif M, Ahmad I, Rasool MF, Shakeel S, et al. (2023). The impact of diabetes mellitus on the emergence of multidrug resistant tuberculosis and treatment failure in TB diabetes comorbid patients: a systematic review and meta-analysis. Front Public Health. 11. doi: 10.3389/fpubh.2023.1244450.
Sahakyan S, Petrosyan V, Abrahamyan L (2020). Diabetes mellitus and treatment outcomes of pulmonary tuberculosis: a cohort study. Int J Public Health. 65(1):37–43. doi: 10.1007/s00038-019-01277-2.
Song Q, Zhang G, Jiang H, Ren Y, Lu X (2016). Imaging features of pulmonary CT in type 2 diabetic patients with multidrug resistant tuberculosis. PLoS One. 11(3):1–11. doi: 10.1371/journal.pone.0152507.
Tegegne BS, Mengesha MM, Teferra AA, Awoke MA, Habtewold TD (2018). Association between diabetes mellitus and multidrug resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst Rev. 7(1). doi: 10.1186/s13643-018-0828-0.
Torres NMC, Rodriguez JJQ, Andrade PSP, Arriaga MB, Netto EM (2019). Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis. PLoS One. 14(12):1–24. doi: 10.1371/journal.pone.0226507.
1.jpg)
